Globus Medical Inc (GMED)
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
- Ticker
- GMED
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Devices
- Market cap
- $9.53B
- 52-week range
- $60.36 - $101.40
Valuation
- Share price
- $71.05 (close of Nov 6, 2026)
- P/E (TTM)
- 17.16x
- Price to book
- 1.99x
- Price to free cash flow
- 12.43x
- Enterprise value
- $9.12B
- Book value per share
- $35.75
Price performance
| Period | Change |
|---|---|
| 1 day | -12.76% |
| 5 days | -8.97% |
| 1 month | -7.04% |
| 3 months | -12.37% |
| 6 months | -20.37% |
| Year to date | -18.62% |
| 1 year | +15.14% |
| 3 years | +52.76% |
| 5 years | -9.39% |
| 10 years | +224.73% |
| All time | +426.30% |
Short interest
- As of
- Oct 15, 2026
- Short % of float
- 7.38%
- Shares short
- 8.19M
- Days to cover
- 5.47
- Change since prior report
- -2.93%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed GMED trades
Gilbert Ray Cisneros · Lisa McClain · Josh Gottheimer
Super investors holding GMED
Ray Dalio (Bridgewater Associates) · Ruane Cunniff (Ruane, Cunniff & Goldfarb L.P.)
Profitability and growth
- Return on equity
- 11.76%
- Return on invested capital
- 8.79%
- Return on assets
- 10.14%
- Return on capital employed
- 9.99%
- Gross margin
- 67.41%
- Net margin
- 18.30%
- EBITDA margin
- 25.75%
- Revenue growth
- 16.65%
- Free cash flow growth
- 45.30%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 8.04%
- Current ratio
- 4.30x
- Net debt to EBITDA
- -0.41x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Revenue
- $2.94B
- Cost of revenue
- $957.80M
- Gross profit
- $1.98B
- EBITDA
- $756.66M
- Net income
- $537.87M
- Earnings per share
- $3.98
- Research and development
- $147.25M
- Shares outstanding
- 135.22M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $2.94B | $1.98B | $537.87M | $3.98 |
| 2024-12-31 | $2.52B | $1.48B | $102.98M | $0.76 |
| 2023-12-31 | $1.57B | $1.02B | $122.87M | $1.09 |
| 2022-12-31 | $1.02B | $759.12M | $190.17M | $1.89 |
| 2021-12-31 | $958.10M | $718.88M | $149.19M | $1.48 |
| 2020-12-31 | $789.04M | $571.58M | $102.28M | $1.04 |
| 2019-12-31 | $785.37M | $605.39M | $155.21M | $1.57 |
| 2018-12-31 | $712.97M | $553.56M | $156.47M | $1.60 |
| 2017-12-31 | $635.98M | $485.52M | $107.35M | $1.12 |
| 2016-12-31 | $563.99M | $429.29M | $104.34M | $1.09 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 67.41% | 18.30% | 11.76% | 8.79% |
| 2024-12-31 | 58.90% | 4.09% | 2.47% | 3.14% |
| 2023-12-31 | 65.05% | 7.83% | 3.07% | 2.01% |
| 2022-12-31 | 74.22% | 18.59% | 10.30% | 9.45% |
| 2021-12-31 | 75.03% | 15.57% | 8.57% | 8.06% |
| 2020-12-31 | 72.44% | 12.96% | 6.79% | 5.81% |
| 2019-12-31 | 77.08% | 19.76% | 11.07% | 9.77% |
| 2018-12-31 | 77.64% | 21.95% | 13.20% | 11.57% |
| 2017-12-31 | 76.34% | 16.88% | 11.09% | 10.26% |
| 2016-12-31 | 76.12% | 18.50% | 12.54% | 12.16% |
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $557.24M | - |
| 2024-12-31 | $890.06M | - |
| 2023-12-31 | $517.79M | $417.40M |
| 2022-12-31 | $446.06M | - |
| 2021-12-31 | $443.45M | - |
| 2020-12-31 | $426.74M | - |
| 2019-12-31 | $311.24M | - |
| 2018-12-31 | $339.58M | - |
| 2017-12-31 | $373.71M | - |
| 2016-12-31 | $290.31M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $588.77M | $49.78M |
| 2024-12-31 | $405.21M | $54.19M |
| 2023-12-31 | $165.22M | $52.74M |
| 2022-12-31 | $104.42M | $32.81M |
| 2021-12-31 | $219.38M | $30.59M |
| 2020-12-31 | $135.13M | $27.07M |
| 2019-12-31 | $101.22M | $26.09M |
| 2018-12-31 | $121.95M | $21.90M |
| 2017-12-31 | $107.75M | $14.69M |
| 2016-12-31 | $106.91M | $11.38M |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-11-05 | Sep 2026 | $1.20 |
| 2026-08-06 | Jun 2026 | $1.12 |
| 2026-05-07 | Mar 2026 | $0.92 |
| 2026-02-24 | Dec 2025 | $1.06 |
| 2025-11-06 | Sep 2025 | $0.79 |
| 2025-08-07 | Jun 2025 | $0.76 |
| 2025-05-08 | Mar 2025 | $0.74 |
| 2025-02-20 | Dec 2024 | $0.76 |
Filings and sources
- Company website
- globusmedical.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Insulet Corp (PODD) · Zimmer Biomet Holdings, Inc. (ZBH) · STERIS plc (STE) · Dexcom Inc (DXCM) · GE HealthCare Technologies Inc. (GEHC) · Edwards Lifesciences Corp (EW) · Boston Scientific Corp (BSX) · Stryker Corp (SYK)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades